Since the outbreak of SARS-CoV-2, there has been queries surrounding the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) in relation to clinical outcomes of COVID-19. This study aims to assess the relationship between use of ACEi or ARB on the clinical outcome of COVID-19.

COMET is being coordinated in the Netherlands with the Northern Health and Social Care Trust acting as the lead UK site. The research team at Medicines Optimisation Innovation Centre (MOIC) and the clinical pharmacy team at Antrim Area Hospital have been working hard to contribute to this international study to learn more about COVID. The growing database has over 4000 patient data sets from more than 60 hospitals across 13 countries.